Table 1.
Demographic and clinical characteristics of the patients and healthy control subjects enrolled in the study
| pSS (n = 9) | ss/SSc (n = 7) | ss/SLE (n = 7) | ss/RA (n = 7) | SSc (n = 7) | SLE (n = 7) | RA (n = 7) | HC (n = 10) | |
|---|---|---|---|---|---|---|---|---|
| Age, years, mean ± SD | 55.8 ± 13 | 63 ± 11 | 51 ± 16 | 61 ± 8 | 60.2 ± 7 | 48. ± 10 | 64.1. ± 9 | 56.6 ± 12.5 |
| Disease duration, years, mean ± SD | 7.9 ± 4.2 | 12 ± 7 | 12 ± 9 | 10 ± 7 | 10.4 ± 8 | 11 ± 8 | 9.4 ± 8 | N/A |
| Anti-Ro/SSA- and/or anti-La/SSB-positive, n | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ANA-positive, n | 6 | 7 | 7 | 1 | 7 | 7 | 2 | 0 |
| RF-positive, n | 5 | 0 | 0 | 6 | 0 | 0 | 4 | 0 |
| Focus score ≥1, n | 6 | 0 | 0 | 0 | N/A | N/A | N/A | 0 |
| UWS <1.5 ml/15 minutes, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Schirmer test result <5 mm/5 minutes, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Xerostomia, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Xerophthalmia, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
Abbreviation: pSS Primary Sjögren’s syndrome, ss Sicca syndrome, SSc Systemic sclerosis, SLE Systemic lupus erythematosus, RA Rheumatoid arthritis, HC Healthy control subjects, UWS Unstimulated whole saliva, ANA Antinuclear antibodies, RF Rheumatoid factor, N/A Not applicable